Pharmacokinetics and safety of a single dose of telavancin in pediatric subjects 2–17 years of age

John S. Bradley, Jennifer L. Goldman, Laura P. James, Byron Kaelin, Breanne H. Y. Gibson, Antonio Arrieta

Open source

DOI
10.1128/aac.00987-23
Published
2023-11-15
Container
Antimicrobial Agents and Chemotherapy
Publisher
American Society for Microbiology
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1128/aac.00987-23,
  title = {Pharmacokinetics and safety of a single dose of telavancin in pediatric subjects 2–17 years of age},
  author = {John S. Bradley and Jennifer L. Goldman and Laura P. James and Byron Kaelin and Breanne H. Y. Gibson and Antonio Arrieta},
  year = {2023},
  journal = {Antimicrobial Agents and Chemotherapy},
  doi = {10.1128/aac.00987-23},
  url = {https://doi.org/10.1128/aac.00987-23}
}

RIS

TY  - JOUR
TI  - Pharmacokinetics and safety of a single dose of telavancin in pediatric subjects 2–17 years of age
AU  - John S. Bradley
AU  - Jennifer L. Goldman
AU  - Laura P. James
AU  - Byron Kaelin
AU  - Breanne H. Y. Gibson
AU  - Antonio Arrieta
PY  - 2023
JO  - Antimicrobial Agents and Chemotherapy
DO  - 10.1128/aac.00987-23
UR  - https://doi.org/10.1128/aac.00987-23
ER  - 

APA

Bradley, J. S., Goldman, J. L., James, L. P., Kaelin, B., Gibson, B. H. Y., & Arrieta, A. (2023). Pharmacokinetics and safety of a single dose of telavancin in pediatric subjects 2–17 years of age. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00987-23

Source records